Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Clinical forensic medicine in Eastern Denmark: Organisation and assessments

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparison of Tenocyte Populations from the Core and Periphery of Equine Tendons

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The key myeloid transcription factor (TF), CEBPA, is frequently mutated in acute myeloid leukemia (AML), but the direct molecular effects of this leukemic driver mutation remain elusive. To investigate CEBPA mutant AML, we performed microscale, in vivo chromatin immunoprecipitation sequencing and identified a set of aberrantly activated enhancers, exclusively occupied by the leukemia-associated CEBPA-p30 isoform. Comparing gene expression changes in human CEBPA mutant AML and the corresponding CebpaLp30 mouse model, we identified Nt5e, encoding CD73, as a cross-species AML gene with an upstream leukemic enhancer physically and functionally linked to the gene. Increased expression of CD73, mediated by the CEBPA-p30 isoform, sustained leukemic growth via the CD73/A2AR axis. Notably, targeting of this pathway enhanced survival of AML-transplanted mice. Our data thus indicate a first-in-class link between a cancer driver mutation in a TF and a druggable, direct transcriptional target.

Original languageEnglish
JournalScientific American
Volume5
Issue number7
Pages (from-to)eaaw4304
ISSN0036-8733
DOIs
Publication statusPublished - 1 Jan 2019

ID: 57758371